Efficacy of TailoredHelicobacter pyloriEradication Treatment Based on Clarithromycin Susceptibility and Maintenance of Acid Secretion

Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole

(2014) S. Sahara et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Eradication of Helicobacter pylori According to 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance

(2013) H. J. Lee et al.   JOURNAL OF INFECTIOUS DISEASES

Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype

(2012) M. Sugimoto et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The effects of varying acidity onHelicobacter pylorigrowth and the bactericidal efficacy of ampicillin

(2012) E. A. Marcus et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report

(2012) Peter Malfertheiner et al.   GUT

Impact of Acid Inhibition on Esophageal Mucosal Injury Induced by Low-Dose Aspirin

(2011) Mitsushige Sugimoto et al.   DIGESTION

Tailored eradication therapy based on fecalHelicobacter pyloriclarithromycin sensitivities

(2008) Takashi Kawai et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

New concepts of resistance in the treatment of Helicobacter pylori infections

(2008) David Y Graham et al.   Nature clinical practice. Gastroenterology & hepatology